#6 Ranibizumab

Overview

This drug therapy inhibits uncontrolled blood vessel formation in the eye, which is the primary cause of age-related macular degeneration, and the leading cause of new blindness in older Americans.

The drug has since become a clinical and commercial success ($700 million in sales since introduction) and remains the standard of care for age-related macular degeneration; new trials are testing combination therapies, which may allow similar or improved outcomes with fewer treatments.

Where Are They Now

The drug has since become a clinical and commercial success (more than $2 billion in sales since introduction) and remains the standard of care for age-related macular degeneration. Intravitreal injection of the drug has been approved recently by the FDA for the treatment of macular edema after retinal vein occlusion. Several new trials are currently ongoing to test combination therapies with drugs such as volociximab and dexamethasone, which may allow similar or improved outcomes with fewer treatments.

Get In Touch With Us